Hyper-Immunoglobin D Syndrome (HIDS)

Cómo pronunciarlo: Síndrome de hiperinmunoglobulina D - hiper-yo-no-glawbin

AiArthritis defines Hyper Immunoglobin-D Syndrome as:

Hyper IgD Syndrome (HIDS), also called mevalonate kinase deficiency (MKD), is a rare autoinflammatory disease caused by a genetic mutation. This mutation affects the mevalonate kinase enzyme, leading to inflammation in the body. Symptoms usually begin in early childhood and happen in episodes, meaning they come and go with periods of little to no symptoms in between.

Download HIDS Fact Sheet
  • Woman in bed checking temperature during a HIDS fever attack, a characteristic recurring symptom of the condition

    Título de la diapositiva

    Write your caption here
    Botón
  • Close-up of mouth ulcers and inflammation, which commonly occur during HIDS flare-ups

    Título de la diapositiva

    Write your caption here
    Botón
  • Person experiencing abdominal pain highlighted in red, a typical symptom during Hyper-Immunoglobin D Syndrome episodes

    Título de la diapositiva

    Write your caption here
    Botón

Symptoms & Characteristics

Common in All AiArthritis Diseases

Flares: Periods of worsening symptoms are called flares. A flare can last for hours, days, weeks, or months.


Physical Activity: Condition improves with activity and exercise and worsens with rest.


Comorbidities: When inflammation is left uncontrolled due to lack of proper treatment, comorbidities can develop. 70% of patients with chronic, lifelong disease will develop comorbidities, including dual or triple diagnoses.


Family History: Autoimmune diseases often run in families, indicating a potential genetic predisposition where that gene can cause disease. Autoinflammatory diseases can occur multiple times in a family, but is based off of genetic mutation. It is not a gene that causes the disease— but a mutation on the gene that can cause the disease which can then be passed on to the next generation.

"Auto" Symptoms

Fatiga: Fatiga o agotamiento severo que puede no aliviarse con cafeína o estimulantes y que puede presentarse incluso después de un largo período de descanso.


Disfunción cognitiva: Niebla mental o periodos de tiempo en los que el pensamiento se nubla y resulta difícil concentrarse.


Síntomas similares a los de la gripe: Sin tener gripe: náuseas, debilidad muscular y malestar general.


Fiebre: Por lo general, el grado es bajo en las enfermedades autoinmunes (con excepción de la artritis idiopática juvenil) y el grado es más alto en las autoinflamatorias (el porcentaje varía mucho según la enfermedad).


Referencia: Estudio sobre los primeros síntomas de la artritis inducida por adyuvante, AiArthritis, 2019.


View Early Symptom Study

Inflammatory Arthritis Symptoms

Stiffness: Severe stiffness in one or more joints, especially in the morning or after sitting for long periods of time. 


Joint Pain: Episodes of joint pain that may last for hours, days, or even weeks, that can appear and disappear suddenly. Often described as “jumping pain” into different locations.


Typically the joint pain will coincide with one or more “Auto” symptoms and start and stop suddenly - for no apparent reason (which is called a "flare"). Some people will experience all of the above symptoms, others only a few.


 If you have any of the arthritis features, and at least one of the “Auto” features, please consult your physician about a referral to a specialist.


Symptoms Often Associated with HIDS

  • Rash
  • Abdominal pain
  • Swollen lymph nodes
  • Mouth sores
  • Nausea
  • Diarrhea
  • Vomiting
  • Headache
  • Enlarged liver and spleen
  • Cough/inflammation of back of throat
  • Seizures
  • Conjunctivitis & uveitis
  • Colitis
  • Cutaneous vasculitis
  • There’s no single test that can confirm a Hyper IgD Syndrome (HIDS) diagnosis, so rheumatologists use a combination of physical exams and a review of family history of autoimmune or autoinflammatory diseases to evaluate symptoms. Genetic testing plays a crucial role in diagnosing HIDS. A blood sample is analyzed to detect mutations in the mevalonate kinase (MVK) gene, which supports the diagnosis of HIDS.


    Blood tests taken during fever episodes to measure inflammation markers, such as CRP and ESR, are also helpful in the diagnostic process. These tests, combined with clinical symptoms and genetic findings, help confirm the diagnosis.


    While ACR and EULAR guidelines do not provide specific protocols for HIDS, they emphasize the importance of genetic testing in diagnosing rare autoinflammatory diseases like HIDS, ensuring an accurate diagnosis and appropriate treatment plan.



  • Opciones de tratamiento para HIDS

    Los tratamientos se adaptan a la enfermedad de cada persona, pero visite nuestra página de Opciones de Tratamiento para obtener más información sobre los diferentes tipos de tratamientos que se utilizan para el HIDS.

  • ¡Necesitamos TU consejo! Rellena este formulario para ofrecer consejos a quienes padecen tu misma enfermedad.

    Envía TU consejo
    • HIDS was first recognized in the 1980s as a periodic fever syndrome caused by mutations in the MVK gene. It is named for the elevated levels of immunoglobulin D (IgD) found in affected patients, which was originally thought to be a key feature of the disease.

    • Only about 200 cases of HIDS have been reported worldwide

    • Europeans are most commonly affected (specifically Dutch and French)

  • Días/Meses de Concientización sobre HIDS


    • World Autoimmune and Autoinflammatory Arthritis Day - May 20th
    • Rare Disease Day - February 29th (28th)
    • Autoimmune Awareness Month - March
    • Rheumatic Disease Awareness Month - September
    • Pain Awareness Month - September
    • Chronic Disease Awareness Day - July 10th
    • Invisible Disabilities Week - 3rd full week of October

  • Otros recursos de HIDS

Con el fin de garantizar que esta página tenga la información más precisa y actualizada, esta página es... Actualmente a la espera de una evaluación médica. Parte de la información está sujeta a cambios.


Última actualización de la página: 31/10/2024